Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522170 · ClinicalTrials.gov registry record
aHUS Observational Long Term Follow-Up
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 94
- Enrollment target
NCT01522170 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 94 participants.
The verdict
NCT01522170 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 94 participants
- Enrollment target
Study Summary
There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2012-03 |
| Est. Completion | 2017-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522170
The ClinicalTrials.gov registry entry for NCT01522170 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01522170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522170 about?
NCT01522170 is a clinical study titled "aHUS Observational Long Term Follow-Up". There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.
What is the current status of trial NCT01522170?
This trial is currently terminated. The enrollment target is 94 participants. The study started on 2012-03. Estimated completion is 2017-01.
Who is sponsoring clinical trial NCT01522170?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.